Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
23 May 2022 - 10:00PM
Business Wire
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage
biotechnology company focused on innovative aesthetic and
therapeutic offerings, today announced that the company will
participate in the William Blair 42nd Annual Growth Stock
Conference, taking place June 6-9, in Chicago. Chief Executive
Officer, Mark Foley, is scheduled to present on Monday, June 6, at
2:00 p.m. CT / 3:00 p.m. ET.
Interested parties can access the live audio webcast for this
conference from the Investor Relations section of the company's
website at www.revance.com. The webcast replay will be available
after the conclusion of the live presentation for 90 days.
About Revance Therapeutics, Inc.
Revance is a commercial stage biotechnology company focused on
innovative aesthetic and therapeutic offerings, including its
next-generation, long-acting neuromodulator product,
DaxibotulinumtoxinA for Injection. Revance has successfully
completed Phase 3 clinical programs for DaxibotulinumtoxinA for
Injection in glabellar (frown) lines, for which the company is
currently pursuing U.S. regulatory approval, and in cervical
dystonia. Revance is also evaluating DaxibotulinumtoxinA for
Injection in adult upper limb spasticity. Revance owns a unique
portfolio of premium products and services for U.S. aesthetics
practices, including the exclusive U.S. distribution rights to the
RHA® Collection of dermal fillers, the first and only range of
FDA-approved fillers for correction of dynamic facial wrinkles and
folds, and the OPUL™ Relational Commerce Platform. Revance has also
partnered with Viatris (formerly Mylan N.V.) to develop a
biosimilar to BOTOX®, which if approved, would be the first and
only generic biosimilar to Botox® and Botox® Cosmetic. For more
information or to join our team visit us at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE
SA.
BOTOX® is a registered trademark of Allergan, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220523005368/en/
Investors Revance Therapeutics, Inc.: Jessica Serra,
626-589-1007 jessica.serra@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476
sfahy@revance.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2024 to May 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From May 2023 to May 2024